Verastem, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Verastem, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 1,091% in 3 years, but profit fell: $479 less profit per $100 of extra sales. Lower than 94% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 0/3Sales grew in 2 of the last 3 years; profit grew in 0 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
−$479Sales grew 1,091% in 3 years, but profit fell: $479 less profit per $100 of extra sales.
Lower than 94% of Healthcare companies in United States.
Asset Productivity Ratio
+1091% / +159%In 3 years sales changed by +1091% while total assets changed by +159%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-25.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 61% of Healthcare companies in United States.
Cash Cushion Ratio
+14%Cash, after subtracting all debt, equals 14% of its market value (net cash).
Higher than 55% of Healthcare companies in United States.
Tangible Assets Ratio
93%Of every $100 the company owns, $93 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 68% of Healthcare companies in United States.
Tangible Net Worth Ratio
71%Of every $100 of net worth, $71 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 57% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Verastem, Inc. made a loss over the last year. Verastem, Inc. owes $0.76 for every $1 it owns. Verastem, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossVerastem, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
18.23The share price is 18.23 times Verastem, Inc.'s book value per share, higher than 93% of Healthcare companies in United States.
Market cap
$911 MThe total market value of all of Verastem, Inc.'s shares at today's price (share price × number of shares), larger than 62% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$50 MWhat Verastem, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.55Net worth divided by the number of shares. The share price of $10.06 is 18.2 times this, which is the P/B above.
Return on equity (ROE)
-471.2%Verastem, Inc. lost 471.2% of its shareholders' money over the last year, lower than 93% of Healthcare companies in United States.
Owes vs Owns
0.76×Verastem, Inc. owes $0.76 for every $1 it owns (moderate), higher than 75% of Healthcare companies in United States.
Dividend yield
NoneVerastem, Inc. does not currently pay a dividend.
Revenue growth
+209%Revenue rose 209% in the year to Dec 2025, and grew 128% a year on average over 3 years.
Profit growth
LossVerastem, Inc. made a loss in each of the last two years.
Profit margin
-677.6%Verastem, Inc. lost $678 for every $100 of revenue.
Interest cover
Not coveredVerastem, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashVerastem, Inc. held $127 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Verastem, Inc.: $911 M ÷ $50 M (30 Jun 2026) = 18.2.
What is Verastem, Inc.'s return on equity?
Verastem, Inc. lost 471.2% of its shareholders' money over the last year, lower than 93% of Healthcare companies in United States.
How much does Verastem, Inc. owe compared with what it owns?
Verastem, Inc. owes $0.76 for every $1 it owns (moderate), higher than 75% of Healthcare companies in United States.
Does Verastem, Inc. pay a dividend?
No. Verastem, Inc. does not currently pay a dividend.
Is Verastem, Inc.'s revenue growing?
Revenue rose 209% in the year to Dec 2025, and grew 128% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.